|
CEREFORT
News
Article on the production and effects of Mitobene in the journal Brauerei Forum (August 2023)
Following successful product development, Cerefort is looking for cooperation partners for further product development and market launch. The aim is to realize a rapid implementation by licensing to breweries and beverage producers with their production and distribution capabilities. Implementation in the brewery is possible without any problems, as existing equipment can be used. Corresponding prototypes have already been developed
More information (in German)
More information (in English)
Cerefort established a scientific advisory board (August 2023)
Cerefort welcomes Prof. Dr. Christine Lang, Peter Majer, Prof. Dr. Heinz Reichmann and Prof. Dr. Burkhard Schütz to its scientific advisory board. This advisory board has extensive expertise in all areas important to Cerefort like strain development, Parkinson's prophylaxis and therapy, mitochondrial analysis and marketing/licensing know-how.
More information
Second study with Mitobene shows promising results (May 2023)
Cerefort has developed a beverage called Mitobene, which is made from grains using a patented fermentation process and has a high D-lactate content. After a first study at the beginning of 2021, another study was conducted at the end of 2022. Several persons took 100 ml of Mitobene daily over a period of 1 month. This study showed that Mitobene has a positive influence on physical performance.
More information
Postitive effect on Mitochondria in the first exploratory pilot study of Cerefort (April 2023)
The participants received a defined daily dose of Mitobene with high D-lactate content. Blood was collected before and at the end of the study. Parameters of mitochondrial activity, like the Bioenergetic Health Index (BHI), were measured by the German diagnostic laboratory Biovis in Marburg. After 6 weeks of Mitobene intake, the BHI index improved and so did important parameters of mitochondrial activity, especially of the Parkinson’s patients.
More information
Article about the development of Mitobene in the journal Brauerei Forum (October 2020)
Based on research by Max Planck scientists, Cerefort GmbH, together with VLB and the Leibnitz Institute of Agricultural Engineering and Bioeconomics, developed an acidic fermented D-lactate-containing soft drink that has a positive effect on mitochondrial integrity and function, thus supporting cellular fitness.
More information (in German)
Foundation of Cerefort to commercialise compounds with a beneficial effect on mitochondria (October 2020)
Cerefort has developed a beverage called Mitobene, which is highly enriched with D-lactate. Mitobene provides all the health-related benefits of fermented foods in addition to its high D-lactate content. The product allows convenient uptake of D-lactate in concentrated form.
More information
|
